Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT.
Adolescent
Adult
Aged
Child
Child, Preschool
Chronic Disease
Female
Hematopoietic Stem Cell Transplantation
/ adverse effects
Herpesvirus 4, Human
/ pathogenicity
Humans
Infant
Lymphoma
/ complications
Male
Middle Aged
Neoplasms
/ complications
Prognosis
Survival Analysis
Transplantation Conditioning
/ adverse effects
Transplantation, Homologous
/ adverse effects
Young Adult
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
05
01
2019
accepted:
20
05
2019
revised:
11
04
2019
pubmed:
1
8
2019
medline:
18
9
2020
entrez:
1
8
2019
Statut:
ppublish
Résumé
The influence of the donor (D) and recipient (R) pre-transplant Epstein-Barr Virus (EBV) serostatus on transplant outcomes (overall survival, relapse-free survival, relapse incidence, non-relapse mortality, acute and chronic GVHD) in 12,931 patients with lymphomas or chronic malignancies undergoing allogeneic hematopoietic cell transplant (allo-HCT) between 1997-2016 was analyzed. In multivariate analysis, the risk of development of chronic GVHD was increased for EBV R+/D+ (HR = 1.26; p = 0.003), R+/D- (HR = 1.21; p = 0.044), and R-/D + (HR = 1.21; p = 0.048) in comparison to R-/D- transplants. No significance was shown for other transplant outcomes; however, in univariate analysis, EBV-seropositive patients receiving grafts from EBV-seropositive donors (EBV R+/D+transplants) had inferior transplant outcomes in comparison to EBV-seronegative recipients of grafts from EBV-seronegative donors (EBV R-/D-): inferior overall survival (59.6% vs 65.9%), inferior relapse-free survival (51.1% vs 57.5%), increased incidence of chronic GVHD (49.5% vs 41.8%), and increased incidence of de novo chronic GVHD (30.5% vs 24.0%). In conclusion, an EBV-negative recipient with lymphoma or chronic malignancy can benefit from selection of an EBV-negative donor in context of chronic GVHD, while there are no preferences in donor EBV serostatus for EBV-seropositive recipient.
Identifiants
pubmed: 31363166
doi: 10.1038/s41409-019-0627-9
pii: 10.1038/s41409-019-0627-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2060-2071Références
Styczynski J, Tridello G, Gil L, Ljungman P, Hoek J, Iacobelli S, et al. Impact of donor epstein-barr virus serostatus on the incidence of graft-versus-host disease in patients with acute leukemia after hematopoietic stem-cell transplantation: a study from the acute leukemia and infectious diseases working parties of the European Society for Blood and Marrow Transplantation. J Clin Oncol. 2016;34:2212–20.
doi: 10.1200/JCO.2015.64.2405
Styczynski J, Reusser P, Einsele H, de la Camara R, Cordonnier C, Ward KN, et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transpl. 2009;43:757–70.
doi: 10.1038/bmt.2008.386
Sundin M, Le Blanc K, Ringden O, Barkholt L, Omazic B, Lergin C, et al. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica. 2006;91:1059–67.
pubmed: 16885046
Curtis RE, Travis LB, Rowlings PA, Socie G, Kingma DW, Banks PM, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999;94:2208–16.
pubmed: 10498590
Styczynski J, Gil L, Tridello G, Ljungman P, Donnelly JP, van der Velden W, et al. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clin Infect Dis. 2013;57:794–802.
doi: 10.1093/cid/cit391
Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304.
doi: 10.1097/00007890-197410000-00001
Iacobelli S. Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation. Bone Marrow Transpl. 2013;48(Suppl 1):S1–37.
doi: 10.1038/bmt.2012.282
Klein JP, Moeschberger ML. Survival analysis: techniques for censored and truncated data. New York: Springer-Verlag; 2003.
Zhang MJ, Fine J. Summarizing differences in cumulative incidence functions. Stat Med. 2008;27:4939–49.
doi: 10.1002/sim.3339
Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17:343–6.
doi: 10.1016/0197-2456(96)00075-X
Zeiser R, Blazar BR. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med. 2017;377:2565–79.
doi: 10.1056/NEJMra1703472
Olivieri J, Manfredi L, Postacchini L, Tedesco S, Leoni P, Gabrielli A, et al. Consensus recommendations for improvement of unmet clinical needs—the example of chronic graft-versus-host disease: a systematic review and meta-analysis. Lancet Haematol. 2015;2:297–305.
doi: 10.1016/S2352-3026(15)00095-2
Malard F, Labopin M, Yakoub-Agha I, Chantepie S, Guillaume T, Blaise D, et al. Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study. Blood. 2017;v130:2186–95.
doi: 10.1182/blood-2017-05-786137
Dai YM, Liu HY, Liu YF, Zhang Y, He W. EBV transformation induces overexpression of hMSH2/3/6 on B lymphocytes and enhances gammadeltaT-cell-mediated cytotoxicity via TCR and NKG2D. Immunology. 2018. https://doi.org/10.1111/imm.12920
doi: 10.1111/imm.12920
Morishima S, Nakamura S, Yamamoto K, Miyauchi H, Kagami Y, Kinoshita T, et al. Increased T-cell responses to Epstein-Barr virus with high viral load in patients with Epstein-Barr virus-positive diffuse large B-cell lymphoma. Leuk Lymphoma. 2015;56:1072–8.
doi: 10.3109/10428194.2014.938326
Cohen JI. Epstein-Barr virus infection. N Engl J Med. 2000;343:481–92.
doi: 10.1056/NEJM200008173430707
Rezvani K, Champlin RE. Epstein-Barr virus and B cells in the pathogenesis of graft-versus-host disease after allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2016;34:2201–2.
doi: 10.1200/JCO.2016.66.6099
de Masson A, Bouaziz JD, Le Buanec H, Robin M, O’Meara A, Parquet N, et al. CD24(hi)CD27(+) and plasmablast-like regulatory B cells in human chronic graft-versus-host disease. Blood. 2015;125:1830–9.
doi: 10.1182/blood-2014-09-599159
Khoder A, Sarvaria A, Alsuliman A, Chew C, Sekine T, Cooper N, et al. Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD. Blood. 2014;124:2034–45.
doi: 10.1182/blood-2014-04-571125
Forcade E, Kim HT, Cutler C, Wang K, Alho AC, Nikiforow S, et al. Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. Blood. 2016;127:2489–97.
doi: 10.1182/blood-2015-12-688895
Styczynski J, van der Velden W, Fox CP, Engelhard D, de la Camara R, Cordonnier C, et al. Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica. 2016;101:803–11.
doi: 10.3324/haematol.2016.144428
Styczyński J, Czyżewski K, Frączkiewicz J, Salamonowicz M, Zając-Spychała O, Zaucha-Prażmo A, et al. Viral infections in children undergoing hematopoietic stem cell transplantation: report 2016 of Polish Pediatric Infectious Working Group of Polish Society of Pediatric Oncology and Hematology. Acta Haematol Pol. 2017;48:23–7. https://doi.org/10.1016/j.achaem.2016.11.006
doi: 10.1016/j.achaem.2016.11.006